Stable Angina — Med2Date

🎧 Stable Angina — deep-dive podcast

📋 Key Information Summary

📋

Stable angina is caused by fixed atherosclerotic coronary stenosis producing predictable exertional chest discomfort relieved by rest or sublingual GTN; it affects approximately 1.2 million Australians and is a leading cause of GP presentations and hospital admissions.
Diagnosis is guided by pre-test probability (PTP) estimation incorporating age, sex, symptom typicality, and risk factors; exercise ECG remains first-line for intermediate PTP (15–65%), while functional imaging or coronary CT angiography (CCTA) is preferred for low-to-intermediate PTP or inconclusive exercise ECG.
The Duke Treadmill Score stratifies exercise ECG results into low, intermediate, and high risk for major adverse cardiovascular events.
First-line anti-anginal therapy is a beta-blocker (e.g. metoprolol, atenolol) or rate-limiting calcium channel blocker (e.g. verapamil, diltiazem); combination therapy is common and should be guided by heart rate, blood pressure, and left ventricular function.
Sublingual glyceryl trinitrate (GTN) is used for acute symptom relief; long-acting nitrates are second-line add-on when beta-blockers or CCBs are inadequate or contraindicated.
Ranolazine (Ranexa®) is a useful third-line agent for refractory angina, particularly when heart rate–limiting drugs are maximised or contraindicated.
All patients require optimal medical therapy (OMT) including antiplatelet (aspirin or clopidogrel), statin, ACE inhibitor/ARB, and antihypertensive therapy before revascularisation is considered.
Revascularisation (PCI or CABG) is indicated when OMT fails to control symptoms (Canadian Cardiovascular Society Class III–IV), when high-risk anatomy is identified (left main >50%, proximal LAD >70%, three-vessel disease with reduced EF), or when prognostic benefit exceeds OMT alone.
The SYNTAX score and Heart Team discussion guide the choice between PCI and CABG; CABG is preferred for high SYNTAX scores (>32) and diabetes with multivessel disease.
Structured cardiac rehabilitation, ≥150 min/week of moderate-intensity exercise, Mediterranean-style diet, smoking cessation, and weight management (target BMI 20–25 kg/m²) are mandatory lifestyle interventions.
Aboriginal and Torres Strait Islander Australians have 1.7–2.0 times the burden of coronary heart disease; culturally safe care, opportunistic cardiovascular screening, and use of Indigenous health workers are essential.
In pregnancy, beta-1–selective blockers (metoprolol) are preferred; statins are contraindicated; nitrates and low-dose aspirin may be continued with specialist input.

Stable Angina clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management — Tap or click image to enlarge — Stable Angina: pathophysiology, clinical clues, diagnosis, imaging, and management.

🎬 Stable Angina — clinical explainer

Introduction & Australian Epidemiology

Stable angina pectoris is the clinical manifestation of chronic, flow-limiting coronary artery disease (CAD) characterised by predictable episodes of chest discomfort provoked by exertion or emotional stress and relieved by rest or sublingual glyceryl trinitrate. It is the most common initial presentation of ischaemic heart disease in primary care and carries significant morbidity if not promptly identified and optimally managed.

In Australia, ischaemic heart disease remains the leading single cause of disease burden, responsible for an estimated 5.1% of total disability-adjusted life years (DALYs) in 2023. The Australian Institute of Health and Welfare (AIHW) reports that approximately 580,000 Australians aged ≥18 years have been diagnosed with coronary heart disease, with stable angina accounting for a substantial proportion of those with preserved left ventricular function. Hospital admissions for chronic ischaemic heart disease (ICD-10 I25) exceed 90,000 episodes annually, and stable angina generates over 2 million GP encounters per year.

Prevalence increases with age and is higher in males, Aboriginal and Torres Strait Islander peoples, and those with conventional cardiovascular risk factors (hypertension, dyslipidaemia, diabetes mellitus, smoking, obesity, and family history of premature CAD). The 2022–2023 National Health Survey estimated that 1 in 14 Australian adults self-report having heart disease, with regional and remote areas showing 20–40% higher hospitalisation rates than major cities.

📊

Australian burden: Coronary heart disease causes ~17,000 deaths per year in Australia. Although age-standardised mortality has declined by ~70% since the 1980s, morbidity from stable angina remains high, with significant impacts on quality of life, work capacity, and healthcare expenditure estimated at $5.6 billion annually (AIHW 2023).

This guideline covers the diagnosis, pharmacological management, revascularisation indications, and lifestyle modification strategies for stable angina, aligned with the National Heart Foundation of Australia / Cardiac Society of Australia and New Zealand (CSANZ) 2023 position statement, the ESC 2019 Chronic Coronary Syndromes guidelines (updated 2024), and current Therapeutic Guidelines (Cardiovascular) recommendations for Australian practice.

Pathophysiology

Stable angina results from an imbalance between myocardial oxygen supply and demand, typically driven by fixed atherosclerotic narrowing of one or more epicardial coronary arteries. Understanding the pathophysiology is essential for rational anti-anginal therapy.

Atherosclerotic Plaque and Flow Limitation

Chronic stable plaques consist of a fibrous cap overlying a lipid-rich necrotic core. Unlike acute coronary syndromes, these plaques are not prone to rupture under resting conditions. Symptoms occur when the stenosis exceeds approximately 50–70% of the vessel lumen diameter on angiography, reducing coronary flow reserve (CFR). During exercise or stress, tachycardia shortens diastolic filling time and increases myocardial oxygen demand (determined by heart rate × systolic blood pressure, i.e. rate-pressure product), precipitating ischaemia.

Coronary Microvascular Dysfunction

Up to 40% of patients with symptoms of stable angina have non-obstructive coronary arteries on angiography. Coronary microvascular dysfunction (CMD) — impaired vasodilatation of pre-arteriolar and arteriolar vessels — may be the underlying mechanism. CMD is more prevalent in women, patients with diabetes, and those with systemic inflammatory conditions. Functional testing with adenosine or regadenoson and measurement of coronary flow reserve (CFR) or index of microcirculatory resistance (IMR) can identify CMD.

Supply–Demand Mismatch Mechanisms

Mechanism	Examples	Clinical Relevance
Reduced supply	Fixed epicardial stenosis, coronary spasm, anaemia, hypoxia, hypotension	Most common; angiographic severity correlates imperfectly with symptoms
Increased demand	Tachycardia, hypertension, LVH, thyrotoxicosis, catecholamine excess	Heart rate control is the cornerstone of anti-anginal therapy
Combined	Exercise in a patient with moderate stenosis and anaemia	Addressing reversible supply/demand factors improves symptoms

Ischaemic Cascade

The ischaemic cascade describes the sequential events: perfusion abnormality → diastolic dysfunction → regional wall motion abnormality → ECG changes → chest pain. This explains why functional imaging (detecting perfusion or wall motion changes) may be more sensitive than exercise ECG in identifying ischaemia, particularly in single-vessel or left circumflex territory disease.

Diagnosis & Risk Assessment

Clinical History and Symptom Characterisation

The clinical history remains the cornerstone of diagnosis. Chest discomfort characteristic of stable angina is described as retrosternal heaviness, tightness, pressure, or squeezing provoked by exertion (e.g. walking uphill, carrying shopping) and relieved within 2–10 minutes by rest or sublingual GTN. Atypical features include radiation to the left arm, jaw, neck, or epigastrium; associated dyspnoea, nausea, or diaphoresis; and provocation by cold weather or heavy meals.

⚠️

Red flags requiring urgent assessment: Rest pain, crescendo pattern (increasing frequency, duration, or severity), haemodynamic instability, new-onset heart failure, or syncope — these suggest unstable angina or acute coronary syndrome, not stable angina, and require immediate cardiology referral and troponin assessment.

Pre-test Probability (PTP) Estimation

The 2019 ESC guidelines recommend estimating PTP of significant CAD using the updated clinical prediction model incorporating age, sex, and symptom typicality. This stratification guides the selection of diagnostic testing.

PTP Category	Probability (%)	Recommended Initial Test
Very low	<5%	No further cardiac testing; consider alternative diagnoses
Low	5–15%	Coronary CT angiography (CCTA) preferred; functional imaging if CCTA contraindicated or equivocal
Intermediate	15–65%	Exercise ECG (if baseline ECG normal and patient able to exercise) or functional imaging (stress echocardiography, myocardial perfusion scintigraphy, cardiac MRI stress)
High	65–90%	Invasive coronary angiography; functional imaging acceptable if high PTP is driven by risk factors rather than typical angina
Very high	>90%	Direct invasive coronary angiography

Stress Testing — Exercise ECG

The Bruce protocol exercise ECG test is widely available across Australian hospitals and private cardiology practices (MBS Item 11712). It is the initial test of choice for patients with intermediate PTP who have a normal resting ECG and can exercise adequately. Sensitivity is approximately 68% and specificity 77%, but the test provides additional prognostic information via the Duke Treadmill Score.

📊

Duke Treadmill Score: DTS = Exercise time (min) − (5 × ST-segment deviation in mm) − (4 × angina index). Low risk (≥+5): 0.25% annual mortality. Intermediate risk (−10 to +4): 1.25% annual mortality. High risk (≤−11): 5.25% annual mortality. Patients in the high-risk category require urgent invasive coronary angiography.

Functional Imaging

Functional testing is preferred when exercise ECG is uninterpretable (left bundle branch block, ventricular pacing, digoxin use, resting ST depression >1 mm, inability to exercise) or when localisation and quantification of ischaemia are needed to guide management.

MBS 61354 / 61358 Myocardial Perfusion Scintigraphy (MPS / SPECT) Stress (pharmacological or exercise) with ⁹⁹ᵐTc-sestamibi or ⁹⁹ᵐTc-tetrofosmin. Sensitivity ~85%, specificity ~80%. Widely available in metropolitan centres. MBS-eligible under nuclear medicine items.

MBS 55121 Stress Echocardiography Dobutamine or exercise stress with transthoracic echocardiography. Detects inducible wall motion abnormalities. Sensitivity ~80%, specificity ~85%. Cost-effective; no radiation exposure. Available in most metropolitan hospitals and some regional centres.

Specialist only Cardiac MRI Stress (CMR perfusion) Adenosine or regadenoson stress perfusion with gadolinium contrast. Highest spatial resolution; sensitivity ~90%, specificity ~85%. Limited availability (major tertiary centres). MBS item 63480 for cardiac MRI (non-MBS for stress perfusion component in most states).

Coronary CT Angiography (CCTA)

CCTA has emerged as a first-line non-invasive anatomical test for low-to-intermediate PTP. It has high sensitivity (~97%) and excellent negative predictive value (~99%), making it highly effective for ruling out obstructive CAD. The SCOT-HEART and PROMISE trials demonstrated that CCTA alters clinical management in 25–40% of patients and reduces myocardial infarction rates compared with standard care.

🏥

Australian access: CCTA (MBS Item 57360) is Medicare-eligible for the investigation of suspected CAD when performed on ≥64-slice CT with prospective gating. Availability is good in metropolitan private radiology and hospital settings; regional access is expanding via teleradiology. CT coronary angiography is preferable to exercise ECG in patients with PTP 5–15% and is increasingly used for PTP 15–50%.

Functional CT — CT-derived fractional flow reserve (CT-FFR or HeartFlow®) — is available at select Australian centres and may reduce the need for downstream invasive angiography when moderate stenoses (40–70%) are detected on CCTA.

Invasive Coronary Angiography

Indicated for high/very-high PTP, high-risk non-invasive test results (DTS ≤−11, extensive ischaemia on imaging, ejection fraction <50%), or when non-invasive testing is inconclusive and clinical suspicion remains high. It is the gold standard for defining coronary anatomy and enables physiological assessment (FFR, iFR) to guide revascularisation decisions. MBS Item 38218 (diagnostic coronary angiography).

Risk Assessment and Prognostic Stratification

Once CAD is confirmed, risk stratification guides intensity of therapy and timing of revascularisation:

Low risk: Normal LV function, single- or two-vessel disease without proximal LAD involvement, negative exercise ECG at high workload, DTS ≥+5. Manage with OMT; revascularisation for symptom control only.
Intermediate risk: Moderate LV dysfunction (EF 35–50%), two-vessel disease with proximal LAD, positive stress test at moderate workload, DTS −10 to +4. Heart Team discussion recommended.
High risk: Severe LV dysfunction (EF <35%), left main stenosis ≥50%, three-vessel disease, proximal LAD stenosis ≥70% with additional vessel disease, high DTS (≤−11), extensive ischaemia (>10% myocardium on imaging). Revascularisation strongly recommended with prognostic benefit.

Medical Therapy

All patients with stable angina require optimal medical therapy (OMT) comprising: (1) anti-anginal agents to improve symptoms and quality of life, and (2) disease-modifying agents to reduce cardiovascular events and mortality. Anti-anginal therapy should be titrated to achieve freedom from symptoms or to reach resting heart rate 55–60 bpm before adding additional agents or considering revascularisation.

First-line Anti-anginal Agents

Beta-Adrenoceptor Blockers

Beta-blockers reduce myocardial oxygen demand by decreasing heart rate, myocardial contractility, and blood pressure. They prolong diastolic filling time, improving coronary perfusion. They are first-line therapy for stable angina, particularly in patients with prior myocardial infarction, reduced ejection fraction, hypertension, or tachyarrhythmias.

💊

Metoprolol Succinate (Toprol-XL®)

Generic · Beta-1 selective blocker

Adult dose 25–50 mg PO BD (immediate release) or 50–200 mg PO daily (controlled release); titrate to resting HR 55–60 bpm

Paediatric dose Not indicated for stable angina in children

Renal adjustment No adjustment required

Hepatic adjustment Consider dose reduction in severe hepatic impairment; start at lowest dose

Key considerations Avoid in severe bradycardia, high-grade AV block, decompensated heart failure, severe asthma. Caution in COPD (cardioselective agents preferred).

PBS status ✔ PBS General Benefit

💊

Atenolol

Tenormin® · Beta-1 selective blocker

Adult dose 50–100 mg PO daily; start 25 mg daily in elderly

Paediatric dose Not indicated

Renal adjustment eGFR 15–35 mL/min: reduce dose to 50 mg daily. eGFR <15: 25 mg daily or avoid

Hepatic adjustment No adjustment required (renally cleared)

PBS status ✔ PBS General Benefit

Rate-limiting Calcium Channel Blockers (CCBs)

Non-dihydropyridine CCBs (verapamil, diltiazem) reduce heart rate and myocardial contractility. They are first-line alternatives to beta-blockers, or can be used in combination when beta-blocker monotherapy is insufficient. Dihydropyridine CCBs (amlodipine, nifedipine) are vasodilators without significant rate-lowering effect and are combined with beta-blockers when additional blood pressure control or coronary vasodilatation is needed.

🚫

Dangerous combination: Do NOT combine verapamil or diltiazem with beta-blockers in patients with reduced ejection fraction (HFrEF) or significant conduction system disease. This combination can cause severe bradycardia, AV block, and decompensated heart failure.

💊

Verapamil Hydrochloride

Isoptin® / Veracaps® · Non-dihydropyridine CCB

Adult dose 80–120 mg PO TDS (immediate release) or 180–480 mg PO daily (SR); titrate over 1–2 weeks

Renal adjustment Use with caution; start at lower dose if eGFR <30 mL/min

Hepatic adjustment Reduce dose by 50–70% in hepatic impairment (high first-pass metabolism)

PBS status ✔ PBS General Benefit

💊

Diltiazem Hydrochloride

Cardizem® / Dilzem® · Non-dihydropyridine CCB

Adult dose 60 mg PO TDS (IR) or 180–360 mg PO daily (SR); titrate to resting HR 55–60 bpm

Renal adjustment No significant adjustment; use with caution in severe impairment

Hepatic adjustment Reduce dose in hepatic impairment; monitor closely

PBS status ✔ PBS General Benefit

💊

Amlodipine Besylate

Norvasc® · Dihydropyridine CCB

Adult dose 5–10 mg PO daily; start 2.5 mg daily in elderly or hepatic impairment

Renal adjustment No adjustment required

Hepatic adjustment Start 2.5 mg daily; titrate slowly

PBS status ✔ PBS General Benefit

Second-line Anti-anginal Agents

Nitrates

Sublingual glyceryl trinitrate (GTN) is used for immediate relief of angina. Long-acting nitrates (isosorbide mononitrate, isosorbide dinitrate) reduce preload and afterload and provide coronary vasodilatation. A nitrate-free interval of 10–14 hours (typically overnight) is essential to prevent tolerance. Long-acting nitrates are second-line add-on therapy when beta-blockers or CCBs are inadequate.

💊

Glyceryl Trinitrate (GTN) — Sublingual

Anginine® / Lycinate®

Adult dose 300–600 mcg sublingual PRN at onset of angina; may repeat every 5 min for up to 3 doses. If no relief after 3 doses, call 000 (suspect ACS).

Onset 1–3 minutes; duration 20–30 minutes

PBS status ✔ PBS General Benefit

💊

Isosorbide Mononitrate (ISMO)

Imdur® / Duride® · Long-acting nitrate

Adult dose 30–60 mg PO daily (modified release, taken in the morning) or 20 mg PO BD (immediate release, with 7-hour gap between doses)

Renal adjustment No significant adjustment; caution in severe impairment

Hepatic adjustment Use with caution in severe hepatic impairment

Key considerations Maintain 10–14 hour nitrate-free interval. Avoid with PDE-5 inhibitors (sildenafil, tadalafil) within 24 hours — risk of severe hypotension.

PBS status ✔ PBS General Benefit

Ranolazine

Ranolazine is a piperazine derivative that inhibits the late sodium current (INa) in myocardial cells, reducing intracellular calcium overload during ischaemia. It reduces angina frequency without significantly affecting heart rate or blood pressure, making it a valuable third-line agent or add-on when rate-lowering drugs are maximised or contraindicated.

💊

Ranolazine

Ranexa® · Late sodium current inhibitor

Adult dose 375 mg PO BD for 1 week, then increase to 500 mg PO BD, maximum 750 mg PO BD

Renal adjustment eGFR 15–30 mL/min: maximum 375 mg BD. eGFR <15: avoid

Hepatic adjustment Child-Pugh A: no adjustment. Child-Pugh B: maximum 375 mg BD. Child-Pugh C: avoid

Key interactions Metabolised via CYP3A4; avoid with strong inhibitors (ketoconazole, diltiazem at high doses, clarithromycin). Moderate inhibitor of CYP2D6 — may increase metoprolol levels.

PBS status ⚠ PBS Authority Required — For patients with angina uncontrolled despite optimal doses of at least two anti-anginal agents

Anti-anginal Combination Strategy

When monotherapy is insufficient, combinations should be chosen based on mechanism, haemodynamic profile, and comorbidities:

Combination	Indication	Cautions
Beta-blocker + Dihydropyridine CCB (amlodipine)	Inadequate symptom control with beta-blocker alone; hypertension comorbidity	Generally safe; monitor for hypotension and peripheral oedema
Beta-blocker + Diltiazem or Verapamil	Refractory angina despite maximised monotherapy; normal EF	Avoid if EF <50%, PR interval >240 ms, or 2nd/3rd degree AV block. Requires specialist supervision.
Beta-blocker + Long-acting nitrate	Add-on for persistent exertional or vasospastic symptoms	Avoid with PDE-5 inhibitors. Maintain nitrate-free interval.
Beta-blocker (or CCB) + Ranolazine	Refractory angina on dual anti-anginal therapy	Check CYP2D6 interaction with metoprolol; adjust doses accordingly.

Disease-Modifying Therapy (Secondary Prevention)

All patients with confirmed CAD require the following regardless of symptom severity:

💊

Aspirin

Cartia® / Astrix® · Antiplatelet

Adult dose 100 mg PO daily (lifelong unless contraindicated). Clopidogrel 75 mg daily if aspirin intolerant.

PBS status ✔ PBS General Benefit

💊

Atorvastatin

Lipitor® · HMG-CoA reductase inhibitor

Adult dose 80 mg PO daily (high-intensity statin for established CAD). Target LDL-C <1.4 mmol/L (ESC) or ≥50% reduction from baseline.

Renal adjustment No dose adjustment; monitor for myopathy in severe renal impairment

PBS status ✔ PBS General Benefit

💊

Perindopril

Coversyl® · ACE inhibitor

Adult dose 5–10 mg PO daily (indicated for all CAD patients, particularly with hypertension, diabetes, LV dysfunction, or CKD)

Renal adjustment Start 2.5 mg daily if eGFR <30 mL/min; titrate with monitoring

PBS status ✔ PBS General Benefit

✅

OPTIMISE mnemonic for OMT: Optimal anti-anginals (beta-blocker/CCB) · Platelet inhibition (aspirin 100 mg) · Target LDL-C (<1.4 mmol/L with high-intensity statin) · Inhibitors of RAAS (ACEi/ARB) · Management of BP (<130/80) · Influenza vaccination annually · Smoking cessation · Exercise and cardiac rehab

Stable Angina visual summary infographic — 🖼️ Stable Angina — visual summary

Revascularisation Indications

Revascularisation by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) should be considered in the context of a Heart Team discussion that weighs symptom burden, anatomical complexity, left ventricular function, comorbidities, and patient preference. It is broadly indicated for: (1) failure of optimal medical therapy to control symptoms, (2) high-risk anatomy where revascularisation offers prognostic benefit over OMT alone, and (3) patient preference after informed shared decision-making.

Indications for Revascularisation

Symptom-driven (CCS Class III–IV)

Persistent angina limiting daily activity despite OMT with ≥2 anti-anginal agents at optimal doses for ≥3 months. Revascularisation improves quality of life and exercise capacity. Prognostic benefit in this setting is modest unless high-risk anatomy is present.

Prognostic benefit — High-risk anatomy

Left main stenosis ≥50%, proximal LAD stenosis ≥70%, three-vessel disease (especially with reduced EF or SYNTAX score >22), two-vessel disease with proximal LAD involvement and reduced EF. Revascularisation in these settings reduces mortality and myocardial infarction rates compared with OMT alone, as demonstrated in the SYNTAX, FREEDOM, and ISCHEMIA trials (for high-risk subgroups).

Objective ischaemia burden

Significant ischaemia affecting ≥10% of the left ventricle on functional imaging, or ischaemia in the LAD territory with demonstrable viability. The ISCHEMIA trial showed that invasive management does not reduce death or MI in patients with moderate ischaemia on OMT, but improves angina-related quality of life.

PCI vs. CABG — Decision Framework

Factor	Favour PCI	Favour CABG
Anatomical complexity	SYNTAX score 0–22 (low)	SYNTAX score 23–32 (intermediate) or ≥33 (high)
Left main disease	Low SYNTAX score, ostial/shaft lesion	Distal bifurcation, high SYNTAX score, LV dysfunction
Diabetes	Single-vessel or simple two-vessel disease	Multivessel disease (FREEDOM trial: CABG superior for MACE reduction)
LV function	Preserved (EF >50%)	Reduced (EF <50%), especially with viable myocardium
Frailty / comorbidity	High surgical risk (STS score >5%), severe COPD, porcelain aorta	Low surgical risk, suitable conduit availability
Patient preference	Desires shorter recovery, less invasive approach	Accepts longer recovery for more durable revascularisation

⚠️

Heart Team discussion: All patients being considered for revascularisation should have their case reviewed by a Heart Team comprising an interventional cardiologist, cardiac surgeon, and the treating physician. This is mandated by ESC guidelines and NHFA/CSANZ recommendations. Documented Heart Team discussion is increasingly expected by Australian accreditation standards (NSQHS).

Key Trial Evidence

Trial	Key Finding	Relevance to Practice
ISCHEMIA (2020)	Invasive strategy vs. OMT in stable CAD with moderate–severe ischaemia: no reduction in death or MI at median 3.2 years; improved angina-related quality of life in patients with baseline angina	Supports OMT as initial strategy; revascularisation primarily for symptom relief unless high-risk anatomy
COURAGE (2007)	PCI + OMT vs. OMT alone: no difference in death or MI; improved symptom control with PCI in CCS class III–IV	OMT is essential regardless of PCI; PCI for residual symptoms
FAME 2 (2014)	FFR-guided PCI + OMT vs. OMT alone in functionally significant stenosis (FFR ≤0.80): reduced urgent revascularisation	Physiological assessment (FFR/iFR) should guide PCI in intermediate stenoses
SYNTAX (2009, 10-year follow-up)	CABG superior to PCI for three-vessel and left main disease with high SYNTAX score	SYNTAX score calculation is mandatory for multivessel disease planning
FREEDOM (2012)	CABG superior to PCI in diabetic patients with multivessel CAD for composite death, MI, stroke	CABG is the preferred revascularisation strategy in diabetes with multivessel disease

Australian Access and MBS Items

PCI is performed at over 60 cardiac catheterisation laboratories across Australia, including regional centres in major states (MBS Item 38300). CABG requires tertiary cardiac surgical services (available in all state capital cities). Access to PCI is generally within 24–48 hours for urgent cases; elective PCI wait times in the public system average 30–60 days. In remote areas, aeromedical retrieval to the nearest PCI-capable centre (primary PCI networks) ensures timely access.

Lifestyle & Risk Factor Modification

Lifestyle modification is a cornerstone of stable angina management and secondary prevention. The 2023 NHFA/CSANZ Position Statement on Cardiovascular Disease Prevention emphasises that lifestyle interventions are as important as pharmacotherapy and should be initiated at the time of diagnosis alongside OMT.

Exercise Prescription

Regular exercise improves exercise capacity, reduces angina frequency, improves endothelial function, and reduces cardiovascular mortality. The exercise prescription should be individualised based on exercise capacity, symptom threshold, and comorbidities.

Aerobic exercise

≥150 min/week of moderate-intensity activity (e.g. brisk walking, cycling, swimming) OR ≥75 min/week of vigorous-intensity activity. Moderate intensity = 50–70% of maximum heart rate (or RPE 11–13 on Borg scale). Ideally spread over 5 days/week in sessions of ≥30 min.

Resistance training

2 sessions/week targeting major muscle groups. Improves muscle strength and functional capacity. Avoid heavy isometric exertion (Valsalva manoeuvre) which may precipitate angina or blood pressure spikes.

Cardiac rehabilitation

Structured outpatient cardiac rehabilitation (Phase II) reduces all-cause mortality by 13–26% and cardiovascular mortality by 20–30%. Referral is mandatory for all CAD patients. Australian programs are typically 6–8 weeks (MBS Items 699, 99200 for group allied health). Wait times in public hospitals average 2–6 weeks; tele-rehabilitation programs are expanding access for regional and remote patients.

Pre-exercise GTN

Patients should use prophylactic sublingual GTN 5 minutes before planned exertion if angina is predictable. Exercise should cease if angina occurs at rest despite GTN — review anti-anginal therapy.

Dietary Modifications

A Mediterranean-style dietary pattern has the strongest evidence base for secondary prevention (PREDIMED trial, Lyon Diet Heart Study). Key recommendations:

Increase: Vegetables (≥5 serves/day), fruits (≥2 serves/day), whole grains, legumes, nuts, seeds, extra-virgin olive oil, oily fish (≥2 serves/week for omega-3 fatty acids).
Reduce: Saturated fat (<7% of total energy), trans fats (avoid), sodium (<2,000 mg/day or <5 g salt/day), added sugars, processed and red meat.
Limit alcohol: ≤10 standard drinks/week; no more than 4 on any single day (NHMRC 2020 Guidelines).
Dietary patterns: Mediterranean diet, DASH diet, or plant-predominant dietary patterns are all associated with 25–30% reduction in major cardiovascular events.

Smoking Cessation

Smoking is the single most modifiable risk factor for CAD progression. Cessation reduces cardiovascular mortality by 36% within 2–5 years. A structured approach combining behavioural support (Quitline 13 7848) with pharmacotherapy is recommended:

💊

Varenicline

Champix® · Nicotinic receptor partial agonist

Adult dose 0.5 mg PO daily for Days 1–3, then 0.5 mg PO BD for Days 4–7, then 1 mg PO BD for 11 weeks (total 12-week course). May repeat once if relapse.

Efficacy Most effective single-agent pharmacotherapy for smoking cessation (OR ~2.2 vs. placebo at 6 months)

Renal adjustment eGFR <30 mL/min: maximum 0.5 mg BD

PBS status ✔ PBS General Benefit — 12-week course, repeatable once

💊

Nicotine Replacement Therapy (NRT)

Nicabate® / Nicorette® · Combination NRT recommended

Adult dose Patch (16–24 hours): 21 mg → 14 mg → 7 mg over 8–12 weeks + PRN oral NRT (gum 2–4 mg, lozenge, spray) for breakthrough cravings

Cardiac safety Safe to use in stable CAD patients; transdermal delivery avoids bolus nicotine effect

PBS status ⚠ PBS Authority Required — Up to 3 courses per lifetime

Weight Management

Obesity (BMI ≥30 kg/m²) and central adiposity (waist circumference >94 cm in men, >80 cm in women) are independent risk factors for CAD progression. Target BMI 20–25 kg/m² (or ≥5% weight loss if obese). Management includes dietary counselling, structured exercise, and consideration of pharmacotherapy (e.g. semaglutide, liraglutide) or bariatric surgery in eligible patients with BMI ≥40 (or ≥35 with comorbidities).

💡

GLP-1 receptor agonists and cardiovascular protection: Semaglutide (Ozempic® / Wegovy®) and liraglutide (Victoza® / Saxenda®) have demonstrated cardiovascular risk reduction in landmark trials (SUSTAIN-6, LEADER, SELECT). These agents are increasingly used in patients with CAD and type 2 diabetes or obesity, in consultation with endocrinology. Semaglutide for weight management (Wegovy®) was TGA-approved in 2024.

Psychosocial Factors

Depression, anxiety, social isolation, and chronic psychosocial stress are common in CAD patients and are independently associated with worse cardiovascular outcomes. Routine screening (PHQ-9, GAD-7) is recommended. Management includes psychological support (cognitive behavioural therapy), social prescribing, and pharmacotherapy for moderate–severe depression (SSRIs are first-line; sertraline and citalopram have the most cardiac safety data).

Special Populations

🤰

Pregnancy

Beta-blockers: Metoprolol (Category B) and labetalol (Category C) are preferred. Avoid atenolol (associated with fetal growth restriction). Bisoprolol is Category C.

Statins: Contraindicated in pregnancy. Cease at least 1 month before conception (Category X — teratogenicity risk). Switch to ezetimibe if needed for lipid management.

Nitrates: GTN may be used; limited safety data for long-acting nitrates. Use with caution.

Aspirin: Low-dose aspirin (100–150 mg) is continued for secondary prevention; also indicated for pre-eclampsia prevention in high-risk women.

Ranolazine: Avoid — limited safety data.

ACE inhibitors / ARBs: Contraindicated in pregnancy (teratogenic: fetopathy, oligohydramnios). Switch to methyldopa, labetalol, or nifedipine for blood pressure control.

Coronary angiography with minimal fluoroscopy and shielding is acceptable if clinically indicated. PCI is preferred over CABG if revascularisation is required during pregnancy. Multidisciplinary management with obstetrics, cardiology, and maternal-fetal medicine is essential.

🧒

Paediatrics

Stable angina is exceedingly rare in the paediatric population. Consider coronary anomalies (anomalous left coronary artery from the pulmonary artery — ALCAPA), Kawasaki disease–associated coronary artery aneurysms, or inherited cardiomyopathies (hypertrophic cardiomyopathy) in children presenting with exertional chest pain.

Kawasaki disease follow-up: Children with coronary aneurysms (z-score ≥2.5) may develop flow-limiting stenoses and angina. Low-dose aspirin (3–5 mg/kg/day) is lifelong for those with persistent aneurysms.

Refer to paediatric cardiology for stress testing and imaging in children with suspected cardiac chest pain. Adult anti-anginal drug doses are not applicable; consult tertiary paediatric cardiology protocols.

👴

Elderly (≥75 years)

The elderly have a higher prevalence of stable angina but are more likely to present with atypical symptoms (dyspnoea, fatigue, syncope rather than classic chest pain). Polypharmacy and multimorbidity necessitate careful medication review.

Beta-blockers: Start at half the usual dose (e.g. metoprolol 12.5–25 mg BD). Monitor for bradycardia, hypotension, fatigue, and falls. Avoid if resting HR <50 bpm or systolic BP <100 mmHg.

CCBs: Amlodipine is well tolerated; verapamil and diltiazem require cautious titration. Monitor for constipation (verapamil) and peripheral oedema (dihydropyridines).

Statins: High-intensity statins remain appropriate; however, consider frailty, life expectancy, and patient goals. Myopathy risk is increased — monitor CK and liver function.

Aspirin: Discuss bleeding risk (GI bleeding, intracranial haemorrhage). Consider concomitant PPI (e.g. esomeprazole 20 mg daily) for gastroprotection.

Revascularisation decisions in the elderly should incorporate frailty assessment (Clinical Frailty Scale), cognitive status, and patient values. CABG carries higher operative risk (EuroSCORE II, STS score); PCI may be preferred with Heart Team agreement.

🫘

Renal Impairment

Chronic kidney disease (CKD) is both a risk factor for CAD and a prognosticator of worse outcomes post-revascularisation. Prevalence of CKD in CAD patients is approximately 30–40%.

Beta-blockers: Metoprolol (hepatically cleared) — no adjustment. Atenolol — dose reduce or avoid in eGFR <30 mL/min (renally cleared).

Ranolazine: Maximum 375 mg BD in eGFR 15–30 mL/min; avoid in eGFR <15.

Statins: Atorvastatin — no dose adjustment (preferred in CKD). Rosuvastatin — maximum 10 mg if eGFR <30 mL/min. Avoid simvastatin >10 mg with concurrent verapamil or diltiazem (myopathy risk).

Contrast for angiography/imaging: Use iso-osmolar or low-osmolar contrast; pre-hydrate with IV saline (1 mL/kg/h for 6–12 hours pre- and post-procedure); limit contrast volume. CKD-EPI eGFR <30 mL/min: discuss risk–benefit with nephrology and interventional cardiology.

Clopidogrel is preferred over ticagrelor or prasugrel if dual antiplatelet therapy is needed (no renal dose adjustment).

🫁

Hepatic Impairment

Verapamil: Reduce dose by 50–70% in hepatic impairment (high first-pass metabolism). Risk of AV block and heart failure.

Amlodipine: Start 2.5 mg daily; titrate slowly.

Metoprolol: Consider dose reduction in severe hepatic impairment; monitor HR and BP closely.

Statins: Use with caution; contraindicated in active liver disease or unexplained persistent transaminase elevations >3× ULN. Atorvastatin and pravastatin have the most favourable hepatic safety profile.

Ranolazine: Child-Pugh A — no adjustment; Child-Pugh B — maximum 375 mg BD; Child-Pugh C — avoid.

Avoid long-acting nitrates in severe hepatic impairment due to increased bioavailability and risk of hypotension.

🛡️

Immunocompromised

Patients with HIV, organ transplant recipients, and those on immunosuppressive therapy have accelerated atherosclerosis and higher rates of stable angina. HIV-associated CAD may involve plaque morphology distinct from traditional atherosclerosis (more non-calcified, inflammatory plaques).

Drug interactions: Protease inhibitors (e.g. ritonavir) significantly inhibit CYP3A4 — avoid verapamil, diltiazem, and ranolazine (risk of toxicity). Use amlodipine with caution. Atorvastatin maximum 20 mg with most protease inhibitors. Consult HIV drug interaction databases (e.g. Liverpool HIV Interaction Checker).

Calcineurin inhibitors: Tacrolimus and cyclosporine increase statin levels — prefer pravastatin or fluvastatin with monitoring of immunosuppressant trough levels.

Cardiac risk assessment should be part of routine cardiovascular screening in immunocompromised patients, with a lower threshold for investigation.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience coronary heart disease at 1.7–2.0 times the rate of non-Indigenous Australians, with earlier onset (10–15 years younger on average), more severe disease at presentation, and higher case-fatality rates. The AIHW reports that cardiovascular disease accounts for approximately 22% of the Indigenous health gap. Culturally safe, person-centred care and community-based health strategies are essential to addressing these disparities.

Prevalence and burden

Age-standardised prevalence of coronary heart disease in First Nations Australians is 6.2% vs. 3.4% in non-Indigenous Australians (ABS National Aboriginal and Torres Strait Islander Health Survey 2018–19). Hospitalisation rates for chronic ischaemic heart disease are 1.8 times higher. Stable angina presentation may be delayed by geographic remoteness and lower health literacy.

Risk factor profile

Smoking prevalence in First Nations adults is ~40% (vs. ~11% non-Indigenous) — the single largest modifiable risk factor. Diabetes prevalence is 3–4 times higher. Obesity, hypertension, and chronic kidney disease are all significantly more prevalent. Rheumatic heart disease contributes additional cardiac morbidity in remote communities.

Geographic and access barriers

Exercise ECG and stress echocardiography may be available only via visiting specialist outreach (e.g. RFDS cardiac outreach) or aeromedical retrieval. CCTA and myocardial perfusion scintigraphy require transfer to regional or metropolitan centres. Angiography and PCI/CABG require transfer to tertiary centres, creating significant disruption and potential reluctance to accept referral.

Cultural considerations

Yarning (culturally appropriate communication) should be used in consultations. Involvement of Aboriginal and Torres Strait Islander health workers and liaison officers improves engagement and medication adherence. Awareness of 'sorry business' and cultural obligations is important when scheduling appointments and rehabilitation programs.

Pharmacotherapy access

PBS Close the Gap (CtG) co-payment measure provides medications at no cost or reduced cost for eligible First Nations patients. Ensure all prescriptions are annotated with the CtG PBS code. Medication availability in remote community stores may be limited; consider long-acting formulations (e.g. long-acting injectable naltrexone for comorbid alcohol use) and blister pack dispensing to improve adherence.

Cardiac rehabilitation

Referral and completion rates for cardiac rehabilitation are significantly lower for First Nations patients (estimated 30% vs. 60% non-Indigenous). Community-controlled health services (ACCHSs) are developing culturally tailored cardiac rehab programs (e.g. Heart Foundation Yarning Circles). Tele-rehabilitation and Indigenous health worker–led exercise programs are emerging models.

Smoking cessation

Intensive, multi-component cessation programs (Quitline + NRT/varenicline + culturally tailored support through ACCHSs) have demonstrated success. The Tackling Indigenous Smoking (TIS) programme provides community-level support. Varenicline and NRT are available under PBS Close the Gap at no cost.

Recommended strategies

Opportunistic cardiovascular risk assessments (MBS Item 715 for Aboriginal and Torres Strait Islander health checks), use of validated tools (AusCVDRisk calculator), proactive recall systems, integration with chronic disease management plans (MBS Item 721), involvement of Indigenous health workers in medication education and adherence support, and pathways for timely specialist review via telehealth (MBS Items 99200, 99203).

📊 Stable Angina — slide deck

Open slides PDF in new tab

📚 References

1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
2. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Australian clinical guidelines for the diagnosis and management of chronic coronary syndromes. Heart Lung Circ. 2023;32(11):1318-1364.
3. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395-1407. doi:10.1056/NEJMoa1915922 (ISCHEMIA trial)
4. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516. doi:10.1056/NEJMoa070829 (COURAGE trial)
5. De Bruyne B, Fearon WF, Pijls NHJ, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208-1217. doi:10.1056/NEJMoa1408758 (FAME 2 trial)
6. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961-972. doi:10.1056/NEJMoa0804626 (SYNTAX trial)
7. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-2384. doi:10.1056/NEJMoa1211585 (FREEDOM trial)
8. SCOT-HEART Investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015;385(9985):2383-2391. doi:10.1016/S0140-6736(15)60291-4
9. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291-1300. doi:10.1056/NEJMoa1415516 (PROMISE trial)
10. Australian Institute of Health and Welfare. Heart, stroke and vascular disease — Australian facts. AIHW, Canberra; 2023. Cat. no. CVD 88.
11. National Health and Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol. NHMRC, Canberra; 2020.
12. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389 (PREDIMED trial)
13. Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67(1):1-12. doi:10.1016/j.jacc.2015.10.044
14. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785. doi:10.1161/01.CIR.99.6.779
15. Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander Health Survey 2018–19. ABS, Canberra; 2019. Cat. no. 4715.0.
16. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141 (SUSTAIN-6 trial)
17. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 (SELECT trial)